Why the study?
Does continuous infusion of doxorubicin prevent cardiotoxicity compared to bolus infusion in children with high-risk acute lymphoblastic leukemia?
Does continuous infusion of doxorubicin prevent cardiotoxicity compared to bolus infusion in children with high-risk acute lymphoblastic leukemia?
Continuous doxorubicin infusion over 48 hours does not offer a cardioprotective advantage over bolus infusion in children with acute lymphoblastic leukemia, as both methods lead to progressive subclinical cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Neither schedule prevents subclinical LV dysfunction in pediatric ALL; challenges infusion-rate cardioprotection and extends need for alternative strategies.
Lipshultz et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: